Citations (83)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (22)
Zeyana Al-Ghafri, Aziz A. Al-Habsi & Michael J. Barry. (2023) Atorvastatin and gemfibrozil alter zebrafish behavior. Marine and Freshwater Behaviour and Physiology 56:3-4, pages 73-89.
Read now
Read now
Lemlem G Gebremichael, Vijayaprakash Suppiah, Michael D Wiese, Lorraine Mackenzie, Craig Phillips, Desmond B Williams & Michael S Roberts. (2021) Efficacy and Safety of Statins in Ethnic Differences: A Lesson for Application in Indigenous Australian Patient Care. Pharmacogenomics 22:9, pages 553-571.
Read now
Read now
Brian Tomlinson, Chen-Hsiu Lin, Paul Chan & Christopher WK Lam. (2021) Personalized Medicine in Lipid-Modifying Therapy. Personalized Medicine 18:2, pages 185-203.
Read now
Read now
Nirmal M. Kasekar, Sarabjit Singh, Kisan R. Jadhav & Vilasrao J. Kadam. (2020) BCS class II drug loaded protein nanoparticles with enhanced oral bioavailability: in vitro evaluation and in vivo pharmacokinetic study in rats. Drug Development and Industrial Pharmacy 46:6, pages 955-962.
Read now
Read now
Jong-Lyul Ghim, Nguyen Thi Thu Phuong, Min Jung Kim, Eun-Ji Kim, Geun Seog Song, Sangzin Ahn, Jae-Gook Shin & Eun-Young Kim. (2019) Pharmacokinetics of fixed-dose combination of atorvastatin and metformin compared with individual tablets. Drug Design, Development and Therapy 13, pages 1623-1632.
Read now
Read now
Shu Yang, Jinping Hu, Yan Li & Zhigang Zhao. (2019) Evaluation of pharmacokinetic interactions between bicyclol and co-administered drugs in rat and human liver microsomes in vitro and in rats in vivo. Xenobiotica 49:8, pages 987-994.
Read now
Read now
Yan Liang, Yimin Cui, Ellen A Cannady, David S Small, Ping Xin, Ming-Dauh Wang, Jian Jun Jin, Xia Zhao & Jeffrey G Suico. (2018) Pharmacokinetics, Pharmacodynamics and Drug Interactions of Evacetrapib with Select Statins in Healthy Chinese Subjects. International Journal of Pharmacokinetics 3:2, pages 69-80.
Read now
Read now
Prashant Tripathi, Harilal Patel, Tanuja Kulshrestha & Nuggehally R Srinivas. (2018) Standard Curve Range for Clinical Sample Analysis of Oral Bioavailability/Bioequivalence Studies: Dilemma, Introspection and Strategies. Bioanalysis 10:10, pages 717-722.
Read now
Read now
Thomas J Dennison, Julian C Smith, Raj K Badhan & Afzal R Mohammed. (2017) Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability. Drug Design, Development and Therapy 11, pages 811-826.
Read now
Read now
Elliot Berinstein & Andrew Levy. (2017) Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments. Expert Opinion on Drug Metabolism & Toxicology 13:9, pages 973-983.
Read now
Read now
Omar Fernando Cruz-Correa, Rafael Baltazar Reyes León-Cachón, Hugo Alberto Barrera-Saldaña & Xavier Soberón. (2017) Prediction of Atorvastatin Plasmatic Concentrations in Healthy Volunteers Using Integrated Pharmacogenetics Sequencing. Pharmacogenomics 18:2, pages 121-131.
Read now
Read now
Joseph P Kitzmiller, Eduard B Mikulik, Anees M Dauki, Chandrama Murkherjee & Jasmine A Luzum. (2016) Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmacogenomics and Personalized Medicine 9, pages 97-106.
Read now
Read now
Takeshi Hirota & Ichiro Ieiri. (2015) Drug–drug interactions that interfere with statin metabolism. Expert Opinion on Drug Metabolism & Toxicology 11:9, pages 1435-1447.
Read now
Read now
Nikica Mirošević Skvrce, Viola Macolić Šarinić, Iveta Šimić, Lana Ganoci, Diana Muačević Katanec & Nada Božina. (2015)
ABCG2 Gene Polymorphisms as Risk Factors for Atorvastatin Adverse Reactions: A Case–Control Study. Pharmacogenomics 16:8, pages 803-815.
Read now
Read now
Brendan D. Stamper. (2015) Transcriptional profiling of reactive metabolites for elucidating toxicological mechanisms: a case study of quinoneimine-forming agents. Drug Metabolism Reviews 47:1, pages 45-55.
Read now
Read now
Euridiki Drogari, Georgia Ragia, Vasiliki Mollaki, Laure Elens, Ron HN Van Schaik & Vangelis G Manolopoulos. (2014)
POR*28 Snp is Associated with Lipid Response to Atorvastatin in Children and Adolescents with Familial Hypercholesterolemia. Pharmacogenomics 15:16, pages 1963-1972.
Read now
Read now
Cheng-Xian Guo, Qi Pei, Ji-Ye Yin, Xiang-Dong Peng, Bo-Ting Zhou, Ying-Chun Zhao, Lan-Xiang Wu, Xiang-Guang Meng, Guo Wang, Qing Li, Dong-Sheng Ouyang, Zhao-Qian Liu, Wei Zhang & Hong-Hao Zhou. (2012) Effects of Ginkgo biloba extracts on pharmacokinetics and efficacy of atorvastatin based on plasma indices. Xenobiotica 42:8, pages 784-790.
Read now
Read now
Isabell Bernlochner, Robert A Byrne, Adnan Kastrati & Dirk Sibbing. (2011) The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders. Expert Review of Cardiovascular Therapy 9:8, pages 999-1014.
Read now
Read now
Virginie Montiel, Vincent Huberlant, Marie-Françoise Vincent, Frédéric Bonbled & Philippe Hantson. (2010) Multiple organ failure after an overdose of less than 0.4 mg/kg of colchicine: role of coingestants and drugs during intensive care management. Clinical Toxicology 48:8, pages 845-848.
Read now
Read now
Justin D Lutz, Yasushi Fujioka & Nina Isoherranen. (2010) Rationalization and prediction of in vivo metabolite exposures: the role of metabolite kinetics, clearance predictions and in vitro parameters. Expert Opinion on Drug Metabolism & Toxicology 6:9, pages 1095-1109.
Read now
Read now
Maria Alice Vieira Willrich, Mario Hiroyuki Hirata & Rosario Dominguez Crespo Hirata. (2009) Statin Regulation of CYP3A4 and CYP3A5 Expression. Pharmacogenomics 10:6, pages 1017-1024.
Read now
Read now
N. R. Srinivas. (2009) Drug–drug interaction studies in preclinical species: should metabolite(s) kinetics be studied?. Xenobiotica 39:3, pages 193-196.
Read now
Read now
Articles from other publishers (61)
Jiamin Chang, Xiaoyu Fan & Boxue Tian. (2024) DeepP450: Predicting Human P450 Activities of Small Molecules by Integrating Pretrained Protein Language Model and Molecular Representation. Journal of Chemical Information and Modeling 64:8, pages 3149-3160.
Crossref
Crossref
Emilia Hoste, Vincent Haufroid, Louise Deldicque, Jean-Luc Balligand & Laure Elens. (2024) Atorvastatin-associated myotoxicity: A toxicokinetic review of pharmacogenetic associations to evaluate the feasibility of precision pharmacotherapy. Clinical Biochemistry 124, pages 110707.
Crossref
Crossref
Yugo Yasugi, Yoshiyuki Shirasaka & Ikumi Tamai. (2023) Quantitative analysis of the impact of membrane permeability on intestinal first‐pass metabolism of CYP3A substrates. Biopharmaceutics & Drug Disposition 45:1, pages 3-14.
Crossref
Crossref
Mohammed G. Maslub, Mahasen A. Radwan, Nur Aizati Athirah Daud & Abubakar Sha’aban. (2023) Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?. European Journal of Medical Research 28:1.
Crossref
Crossref
Fikri A.R. Hardiyanti Oktavia, Ngoc Anh Nguyen, Chan Mi Park, Gun Su Cha, Thi Huong Ha Nguyen & Chul-Ho Yun. (2023) CYP102A1 peroxygenase catalyzed reaction via in situ H2O2 generation. Journal of Inorganic Biochemistry 242, pages 112165.
Crossref
Crossref
Ana Salomé Correia, Lara Marques & Nuno Vale. (2023) The Involvement of Hypoxia in the Response of Neuroblastoma Cells to the Exposure of Atorvastatin. Current Issues in Molecular Biology 45:4, pages 3333-3346.
Crossref
Crossref
Koichiro Adachi, Katsuhiro Ohyama, Yoichi Tanaka, Tasuku Sato, Norie Murayama, Makiko Shimizu, Yoshiro Saito & Hiroshi Yamazaki. (2023) High hepatic and plasma exposures of atorvastatin in subjects harboring impaired cytochrome P450 3A4∗16 modeled after virtual administrations and possibly associated with statin intolerance found in the Japanese adverse drug event report database. Drug Metabolism and Pharmacokinetics 49, pages 100486.
Crossref
Crossref
Zebin Jiang, Zemin Wu, Ruixue Liu, Qin Du, Xian Fu, Min Li, Yongjun Kuang, Shen Lin, Jiaxuan Wu, Weiji Xie, Ganggang Shi, Yanqiang Peng & Fuchun Zheng. (2023) Effect of polymorphisms in drug metabolism and transportation on plasma concentration of atorvastatin and its metabolites in patients with chronic kidney disease. Frontiers in Pharmacology 14.
Crossref
Crossref
Javier Reig-López, Matilde Merino-Sanjuan, Alfredo García-Arieta & Victor Mangas-Sanjuán. (2022) A physiologically based pharmacokinetic model for open acid and lactone forms of atorvastatin and metabolites to assess the drug-gene interaction with SLCO1B1 polymorphisms. Biomedicine & Pharmacotherapy 156, pages 113914.
Crossref
Crossref
Jin-Woo Park, Jong-Min Kim, Hwa-Young Lee, Jihyeon Noh, Kyoung-Ah Kim & Ji-Young Park. (2022) CYP3A5*3 and SLCO1B1 c.521T>C Polymorphisms Influence the Pharmacokinetics of Atorvastatin and 2-Hydroxy Atorvastatin. Pharmaceutics 14:7, pages 1491.
Crossref
Crossref
Mo’tasem M. Alsmadi, Nour M. AL-Daoud, Rana M. Obaidat & Niazy A. Abu-Farsakh. (2022) Enhancing Atorvastatin In Vivo Oral Bioavailability in the Presence of Inflammatory Bowel Disease and Irritable Bowel Syndrome Using Supercritical Fluid Technology Guided by wbPBPK Modeling in Rat and Human. AAPS PharmSciTech 23:5.
Crossref
Crossref
Emmanuel Eysseric, Christian Gagnon & Pedro A. Segura. (2022) Uncovering transformation products of four organic contaminants of concern by photodegradation experiments and analysis of real samples from a local river. Chemosphere 293, pages 133408.
Crossref
Crossref
Ioannis Stouras, Theodore Papaioannou, Konstantinos Tsioufis, Aristides Eliopoulos & Despina Sanoudou. (2022) The Challenge and Importance of Integrating Drug–Nutrient–Genome Interactions in Personalized Cardiovascular Healthcare. Journal of Personalized Medicine 12:4, pages 513.
Crossref
Crossref
Nada Božina, Lana Ganoci, Livija Simičević, Katarina Gvozdanović, Iva Klarica Domjanović, Margareta Fistrek Prlić, Tena Križ, Ana Borić Bilušić, Mario Laganović & Tamara Božina. (2021) Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review. Archives of Industrial Hygiene and Toxicology 72:2, pages 114-128.
Crossref
Crossref
Javier Reig-López, Alfredo García-Arieta, Víctor Mangas-Sanjuán & Matilde Merino-Sanjuán. (2021) Current Evidence, Challenges, and Opportunities of Physiologically Based Pharmacokinetic Models of Atorvastatin for Decision Making. Pharmaceutics 13:5, pages 709.
Crossref
Crossref
Pablo Zubiaur, Maria Dolores Benedicto, Gonzalo Villapalos-García, Marcos Navares-Gómez, Gina Mejía-Abril, Manuel Román, Samuel Martín-Vílchez, Dolores Ochoa & Francisco Abad-Santos. (2021) SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability. Journal of Personalized Medicine 11:3, pages 204.
Crossref
Crossref
He-Ping Lei, Min Qin, Li-Yun Cai, Hong Wu, Lan Tang, Ju-E Liu, Chun-Yu Deng, Yi-Bin Liu, Qian Zhu, Han-Ping Li, Wei Hu, Min Yang, Yi-Zhun Zhu & Shi-Long Zhong. (2021) UGT1A1 rs4148323 A Allele is Associated With Increased 2-Hydroxy Atorvastatin Formation and Higher Death Risk in Chinese Patients With Coronary Artery Disease. Frontiers in Pharmacology 12.
Crossref
Crossref
Thi Nguyen, Soo-Jin Yeom & Chul-Ho Yun. (2021) Production of a Human Metabolite of Atorvastatin by Bacterial CYP102A1 Peroxygenase. Applied Sciences 11:2, pages 603.
Crossref
Crossref
Lovekesh Mehta, Parul Grover, Tanveer Naved & Debaraj Mukherjee. (2021) Metabolite Detection and Profiling Using Analytical Methods. Current Pharmaceutical Analysis 17:1, pages 2-9.
Crossref
Crossref
Alaa S. Tulbah. (2020) The potential of Atorvastatin for chronic lung diseases therapy. Saudi Pharmaceutical Journal 28:11, pages 1353-1363.
Crossref
Crossref
Rossana Roncato, Jacopo Angelini, Arianna Pani, Erika Cecchin, Andrea Sartore-Bianchi, Salvatore Siena, Elena De Mattia, Francesco Scaglione & Giuseppe Toffoli. (2020) CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions. International Journal of Molecular Sciences 21:17, pages 6350.
Crossref
Crossref
Yiting Yang & Xiaodong Liu. (2020) Imbalance of Drug Transporter-CYP450s Interplay by Diabetes and Its Clinical Significance. Pharmaceutics 12:4, pages 348.
Crossref
Crossref
Moustapha E. Moustapha. (2020) Radioiodination of Atorvastatin as a Model Radiopharmaceutical for Targeting Liver. Radiochemistry 62:4, pages 532-538.
Crossref
Crossref
Richard Myles Turner & Munir Pirmohamed. (2019) Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components. Journal of Clinical Medicine 9:1, pages 22.
Crossref
Crossref
Nora Lee, Kazuya Maeda, Shinya Fukizawa, Ichiro Ieiri, Atsuko Tomaru, Hironobu Akao, Kenji Takeda, Mizuho Iwadare, Osamu Niwa, Tougen Masauji, Naoe Yamane, Kouji Kajinami, Hiroyuki Kusuhara & Yuichi Sugiyama. (2019) Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients. Drug Metabolism and Pharmacokinetics 34:6, pages 387-395.
Crossref
Crossref
Jacqueline Wen Hui Leow & Eric Chun Yong Chan. (2019) Atypical Michaelis-Menten kinetics in cytochrome P450 enzymes: A focus on substrate inhibition. Biochemical Pharmacology 169, pages 113615.
Crossref
Crossref
William McKeand, Susan Baird‐Bellaire, James Ermer & Alain Patat. (2018) A Study of the Potential Interaction Between Bazedoxifene and Atorvastatin in Healthy Postmenopausal Women. Clinical Pharmacology in Drug Development 7:8, pages 911-919.
Crossref
Crossref
Liang Gong, Cong-Min Zhang, Jin-Feng Lv, Hong-Hao Zhou & Lan Fan. (2017) Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy. Pharmacogenetics and Genomics 27:9, pages 337-346.
Crossref
Crossref
Deepanshu Shilpi, Varun Kushwah, Ashish Kumar Agrawal & Sanyog Jain. (2017) Improved Stability and Enhanced Oral Bioavailability of Atorvastatin Loaded Stearic Acid Modified Gelatin Nanoparticles. Pharmaceutical Research 34:7, pages 1505-1516.
Crossref
Crossref
Ayman F. El‐Kattan. 2017. Oral Bioavailability Assessment. Oral Bioavailability Assessment
173
201
.
Jonathan Martens, Valerie Koppen, Giel Berden, Filip Cuyckens & Jos Oomens. (2017) Combined Liquid Chromatography-Infrared Ion Spectroscopy for Identification of Regioisomeric Drug Metabolites. Analytical Chemistry 89:8, pages 4359-4362.
Crossref
Crossref
Chang-Soon Yim, Yoo-Seong Jeong, Song-Yi Lee, Wonji Pyeon, Heon-Min Ryu, Jong-Hwa Lee, Kyeong-Ryoon Lee, Han-Joo Maeng & Suk-Jae Chung. (2017) Specific Inhibition of the Distribution of Lobeglitazone to the Liver by Atorvastatin in Rats: Evidence for a Rat Organic Anion Transporting Polypeptide 1B2–Mediated Interaction in Hepatic Transport. Drug Metabolism and Disposition 45:3, pages 246-259.
Crossref
Crossref
Koya Fukunaga, Hiroshi Nakagawa, Toshihisa Ishikawa, Michiaki Kubo & Taisei Mushiroda. (2016) ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population. BMC Genetics 17:1.
Crossref
Crossref
Neville F. Ford. (2016) The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway. The Journal of Clinical Pharmacology 56:12, pages 1474-1483.
Crossref
Crossref
Ju-E Liu, Bin Ren, Lan Tang, Qian-Jie Tang, Xiao-Ying Liu, Xin Li, Xue Bai, Wan-Ping Zhong, Jin-Xiu Meng, Hao-Ming Lin, Hong Wu, Ji-Yan Chen & Shi-Long Zhong. (2016) The independent contribution of miRNAs to the missing heritability in CYP3A4/5 functionality and the metabolism of atorvastatin. Scientific Reports 6:1.
Crossref
Crossref
Tony K. L. Kiang, Kyle John Wilby & Mary H. H. Ensom. 2016. Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antiretroviral Drugs. Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antiretroviral Drugs
79
120
.
Tony K. L. Kiang, Kyle John Wilby & Mary H. H. Ensom. 2016. Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antiretroviral Drugs. Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antiretroviral Drugs
43
78
.
Kan-kan Wei & Li-rong Zhang. (2015) Interactions Between CYP3A5*3 and POR*28 Polymorphisms and Lipid Lowering Response with Atorvastatin. Clinical Drug Investigation 35:9, pages 583-591.
Crossref
Crossref
P.C. Orsolin, R.G. Silva-Oliveira & J.C. Nepomuceno. (2015) Modulating effect of synthetic statins against damage induced by doxorubicin in somatic cells of Drosophila melanogaster. Food and Chemical Toxicology 81, pages 111-119.
Crossref
Crossref
Swagatika Sahoo, Hulda S. Haraldsdóttir, Ronan M. T. Fleming & Ines Thiele. (2014) Modeling the effects of commonly used drugs on human metabolism. The FEBS Journal 282:2, pages 297-317.
Crossref
Crossref
F. Peter Guengerich. 2015. Cytochrome P450. Cytochrome P450
523
785
.
Albert Braeuning, Philip Bucher, Ute Hofmann, Albrecht Buchmann & Michael Schwarz. (2014) Chemically induced mouse liver tumors are resistant to treatment with atorvastatin. BMC Cancer 14:1.
Crossref
Crossref
Bao-xia He, Lei Shi, Jian Qiu, Xiao-Hui Zeng & Shu-Jin Zhao. (2014) The effect of CYP3A4*1G allele on the pharmacokinetics of atorvastatin in Chinese han patients with coronary heart disease. The Journal of Clinical Pharmacology 54:4, pages 462-467.
Crossref
Crossref
Georgia Ragia, Vana Kolovou, Anna Tavridou, Laure Elens, Alexandros D. Tselepis, Moses Elisaf, Ron H. N. Van Schaik, Genovefa Kolovou & Vangelis G. Manolopoulos. (2014) Lack of Association of the P450 Oxidoreductase *28 Single Nucleotide Polymorphism with the Lipid-Lowering Effect of Statins in Hypercholesterolemic Patients. Molecular Diagnosis & Therapy.
Crossref
Crossref
Feixiong Cheng. 2014. Handbook of Metabolic Pathways of Xenobiotics. Handbook of Metabolic Pathways of Xenobiotics
1
5
.
Hassan MalekinejadVahid Shafie-IrannejadRahim HobbenaghiSeyed Hamed TabatabaieSeyed-Mehdi Moshtaghion. (2013) Comparative Protective Effect of Hawthorn Berry Hydroalcoholic Extract, Atorvastatin, and Mesalamine on Experimentally Induced Colitis in Rats. Journal of Medicinal Food 16:7, pages 593-601.
Crossref
Crossref
Sai Wang Seto, Alice Lai Shan Au, Christina Chui Wa Poon, Qian Zhang, Rachel Wai Sum Li, John Hok Keung Yeung, Siu Kai Kong, Sai Ming Ngai, Song Wan, Ho Pui Ho, Simon Ming Yuen Lee, Maggie Pui Man Hoi, Shun Wan Chan, George Pak Heng Leung & Yiu Wa Kwan. (2013) Acute Simvastatin Inhibits KATP Channels of Porcine Coronary Artery Myocytes. PLoS ONE 8:6, pages e66404.
Crossref
Crossref
Renli Teng, Patrick D. Mitchell & Kathleen A. Butler. (2012) Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. European Journal of Clinical Pharmacology 69:3, pages 477-487.
Crossref
Crossref
Miao Hu, Valiant W.L. Mak & Brian Tomlinson. (2013)
Comments on
“CYP3AP1
*3 Allele Is Associated With Lipid‐Lowering Efficacy of Simvastatin and Atorvastatin in Chinese Women”
. The Journal of Clinical Pharmacology 52:11, pages 1768-1769.
Crossref
Crossref
Miroslav Dostalek, Wai-Johnn Sam, Komal R. Paryani, Joyce S. Macwan, Reginald Y. Gohh & Fatemeh Akhlaghi. (2012) Diabetes Mellitus Reduces the Clearance of Atorvastatin Lactone. Clinical Pharmacokinetics 51:9, pages 591-606.
Crossref
Crossref
Patrizia Gazzerro, Maria Chiara Proto, Giuseppina Gangemi, Anna Maria Malfitano, Elena Ciaglia, Simona Pisanti, Antonietta Santoro, Chiara Laezza & Maurizio Bifulco. (2012) Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer. Pharmacological Reviews 64:1, pages 102-146.
Crossref
Crossref
Joachim Bucher, Stephan Riedmaier, Anke Schnabel, Katrin Marcus, Gabriele Vacun, Thomas S Weiss, Wolfgang E Thasler, Andreas K Nüssler, Ulrich M Zanger & Matthias Reuss. (2011) A systems biology approach to dynamic modeling and inter-subject variability of statin pharmacokinetics in human hepatocytes. BMC Systems Biology 5:1.
Crossref
Crossref
Jaekyu Shin, Daniel F. Pauly, Michael A. Pacanowski, Taimour Langaee, Reginald F. Frye & Julie A. Johnson. (2012) Effect of Cytochrome P450 3A5 Genotype on Atorvastatin Pharmacokinetics and Its Interaction with Clarithromycin. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 31:10, pages 942-950.
Crossref
Crossref
Patrick Reddy, David Ellington, Yiliang Zhu, Immo Zdrojewski, Sarah J. Parent, Jerold S. Harmatz, Hartmut Derendorf, David J. Greenblatt & Kevin Browne, Jr. (2011) Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. British Journal of Clinical Pharmacology 72:3, pages 434-441.
Crossref
Crossref
D Wang, Y Guo, S A Wrighton, G E Cooke & W Sadee. (2010) Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. The Pharmacogenomics Journal 11:4, pages 274-286.
Crossref
Crossref
Yan-Peng Li, Li-rong Zhang, Min Jia & Xiang-Jie Hu. (2011)
CYP3AP1*3
Allele Is Associated With Lipid-Lowering Efficacy of Simvastatin and Atorvastatin in Chinese Women
. The Journal of Clinical Pharmacology 51:2, pages 181-188.
Crossref
Crossref
David S. Small, Nagy A. Farid, Christopher D. Payne, Christopher S. Konkoy, Joseph A. Jakubowski, Kenneth J. Winters & Daniel E. Salazar. (2010) Effect of Intrinsic and Extrinsic Factors on the Clinical Pharmacokinetics and Pharmacodynamics of Prasugrel. Clinical Pharmacokinetics 49:12, pages 777-798.
Crossref
Crossref
Keiko Maekawa, Noriko Harakawa, Takuya Yoshimura, Su-Ryang Kim, Yoshiyuki Fujimura, Fumika Aohara, Kimie Sai, Noriko Katori, Masahiro Tohkin, Mikihiko Naito, Ryuichi Hasegawa, Haruhiro Okuda, Jun-ichi Sawada, Takuro Niwa & Yoshiro Saito. (2010)
CYP3A4
*
16
and
CYP3A4
*
18
Alleles Found in East Asians Exhibit Differential Catalytic Activities for Seven CYP3A4 Substrate Drugs
. Drug Metabolism and Disposition 38:12, pages 2100-2104.
Crossref
Crossref
Diana M. Feidt, Kathrin Klein, Ute Hofmann, Stephan Riedmaier, Daniel Knobeloch, Wolfgang E. Thasler, Thomas S. Weiss, Matthias Schwab & Ulrich M. Zanger. (2010) Profiling Induction of Cytochrome P450 Enzyme Activity by Statins Using a New Liquid Chromatography-Tandem Mass Spectrometry Cocktail Assay in Human Hepatocytes. Drug Metabolism and Disposition 38:9, pages 1589-1597.
Crossref
Crossref
Kristian M. BaileySimon P.R. RomaineBeryl M. JacksonAmanda J. FarrinMaria EfthymiouJulian H. BarthJoanne CopelandTerry McCormackAndrew WhiteheadMarcus D. FlatherNilesh J. SamaniJane NixonAlistair S. HallAnthony J. Balmforth. (2010) Hepatic Metabolism and Transporter Gene Variants Enhance Response to Rosuvastatin in Patients With Acute Myocardial Infarction. Circulation: Cardiovascular Genetics 3:3, pages 276-285.
Crossref
Crossref
Toshiro Niwa, Norie Murayama & Hiroshi Yamazaki. (2010) Comparison of the Contributions of Cytochromes P450 3A4 and 3A5 in Drug Oxidation Rates and Substrate Inhibition. Journal of Health Science 56:3, pages 239-256.
Crossref
Crossref